AIM-listed Tissue Regenix has agreed seven sales distribution agreements in the US to promote its DermaPure human skin replacement device into hospitals. Shares in the company jumped over 16% to 20.13p as the company confirmed it was on course for 2014 commercial launch for its first product to be commercialised on a large scale, with six further distribution deals planned to achieve national coverage.DermaPure is the company's human product for chronic wounds, where donor tissue from a human is 'decellularised' to make it compatible with the tissue in the patient.Greg Bila, President of US subsidiary Tissue Regenix Wound Care, said: "These agreements allow us to launch our institutional sales strategy, and we are working hard with the distributors to bring the product to market. "With a significant distribution footprint now in place across the US, we remain steadily on course for the North American commercial launch of DermaPure in 2014."Panmure Gordon said the agreements should allow a "strong entry" into the US market with "disruptive technology, taking on the incumbents head on". It added that regenerative medicine was a hot area and it foresaw a "likely" trade sale. House broker Jefferies was ebullient in its praise of its client: "After three years as a listed company, Tissue Regenix is becoming an investable medtech company. With an imminent first product launch, we see scope for the shares to double in value as the story de-risks and first sales are generated."OH